We are live on
!
Find out more
SGA
Sector Gamma AS Portfolio holdings
AUM
$423M
1-Year Est. Return
17.56%
This Fund
S&P 500
This Quarter
Est. Return
-14.12%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$469M
AUM Growth
-$155M
(-25%)
Cap. Flow
-$70.4M
Cap. Flow
% of AUM
-15.02%
Top 10 Holdings %
Top 10 Hldgs %
55.66%
Holding
40
New
3
Increased
12
Reduced
16
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Incyte
INCY
|
+$12.8M |
| 2 |
CVS Health
CVS
|
+$8.07M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$6.28M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$5.57M |
| 5 |
LivaNova
LIVN
|
+$4.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$17.6M |
| 2 |
Abbott
ABT
|
+$16.3M |
| 3 |
Gilead Sciences
GILD
|
+$14.9M |
| 4 |
Qiagen
QGEN
|
+$14.7M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$10.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ultragenyx Pharmaceutical
RARE
$2.56B
| $6.45M | 1.37% |
145,072
-70,124
| -33% | -$3.64M |
|
|
27
Alnylam Pharmaceuticals
ALNY
$38.5B
| $5.92M | 1.26% |
+54,384
| New | +$6.28M |
|
28
PTC Therapeutics
PTCT
$6.25B
| $3.39M | 0.72% |
75,996
-24,206
| -24% | -$1.22M |
|
|
29
LivaNova
LIVN
$4.51B
| $3.23M | 0.69% |
+71,400
| New | +$4.62M |
|
|
CLVS
30
DELISTED
Clovis Oncology, Inc.
CLVS
| $2.39M | 0.51% |
376,085
-32,540
| -8% | -$261K |
|
|
BLUE
31
DELISTED
bluebird bio
BLUE
| $2.23M | 0.48% |
3,743
-1,074
| -22% | -$1.05M |
|
32
Agios Pharmaceuticals
AGIO
$2.14B
| – | – |
-63,913
| Closed | -$3.05M |
|
33
Eli Lilly
LLY
$1.09T
| – | – |
-15,524
| Closed | -$2.04M |
|
|
34
Qiagen
QGEN
$8.72B
| – | – |
-409,391
| Closed | -$14.7M |
|
|
35
Regeneron Pharmaceuticals
REGN
$72.9B
| – | – |
-28,458
| Closed | -$10.7M |
|
|
SGMO
36
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| – | – |
-211,698
| Closed | -$1.77M |
|
37
Takeda Pharmaceutical
TAK
$56B
| – | – |
-30,873
| Closed | -$609K |
|
38
Tenet Healthcare
THC
$22.6B
| – | – |
-170,896
| Closed | -$6.5M |
|
39
Universal Health Services
UHS
$10.1B
| – | – |
-65,864
| Closed | -$9.45M |
|
|
PTLA
40
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-130,625
| Closed | -$3.12M |
|
Similar funds
AFWM
DS
RS
DF
OGM
CPIM
MPPLM
GPA
Sector Gamma AS's Q1 2020 Portfolio in Review
As of Q1 2020, Sector Gamma AS held 40 positions worth $469M, down 25% from $624M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Sector Gamma AS withdrew a net $70.4M in Q1 2020, closing 9 positions and reducing 16 holdings. Its most notable exit was Qiagen, an estimated $14.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.
Against the trend, Sector Gamma AS opened a new position in CVS Health worth $7.17M.
- Sector Gamma AS's largest Q1 2020 buy was CVS Health: 120,860 shares worth $7.17M.
- Sector Gamma AS added most to Incyte in Q1 2020, an estimated $12.8M increase.
- Sector Gamma AS's biggest Q1 2020 reduction was Bristol-Myers Squibb, cutting an estimated $17.6M.
- Sector Gamma AS fully exited Qiagen in Q1 2020, selling an estimated $14.7M.
- Sector Gamma AS's ten largest holdings make up 56% of its $469M portfolio in Q1 2020.
- Sector Gamma AS opened 3 new positions and closed 9 in Q1 2020.
- Sector Gamma AS's portfolio value fell 25% quarter-over-quarter to $469M.
Based on Sector Gamma AS's 13F filing for Q1 2020, filed 11 May 2020.